glp-1 agonist eli lilly Drugmaker announced that the FDA approved its daily pill, which will be marketed under the name Foundayo, to treat obesity. ABC News' Youri Benadjaoud reports. https://abcnewslive.visitlink.me/pYGbNh Medscape | Orforglipron, Eli Lilly's

In the OASIS 4 randomized, placebo-controlled trial, oral semaglutide demonstrated statistically significant and clinically meaningful reductions in body weight (~1417%) compared with placebo, consistent with the GLP-1 mechanism of action

Contact us today to start your journey to your best self

If youd like to find out why we took profit on our MedTech shorts, or find out when we booked a +300% gain on CURV, read about how recent developments have informed our allocation etc

48,49 Investigating GLP-1 agonism could provide critical insights into restoring metabolic homeostasis in aging tissues and may expand the therapeutic scope of GLP-1 RAs beyond their current indications

Prior authorization criteria for Rezdiffra vary by insurance, but I know some plans require the following: (1) MASH diagnosis by liver biopsy, Fibroscan, or magnetic resonance elastography (MRE), (2) prescribed by a gastroenterologist or hepatologist